NCT04277247 - Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 12, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

Dystonia DisorderParkinson Disease

Interventions

DRUG

Botulinum toxin type A

A standardized dose will be injected in each muscle: 25 Units of BTXA in the extensor hallucis longus in 1 site, 50 Units of BTXA in the flexor digitorum brevis in 2 sites and 25 Units of BTXA in the tibialis posterior in 1 site.

DRUG

Placebo

0.9% saline placebo injection

Trial Locations (1)

T2N4Z1

RECRUITING

Movement Disorder Program, Foothills Medical Center, Alberta Health Services, Calgary